Results 71 to 80 of about 117 (84)

Efficacy after 1 and 2 doses of CYD-TDV in dengue endemic areas by dengue serostatus

Vaccine, 2020
Fernando Noriega
exaly  

Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine

Lancet Infectious Diseases, The, 2019
Annelies Wilder-Smith, Neil Ferguson, Alan D T Barrett   +2 more
exaly  

CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety

Journal of Comparative Effectiveness Research, 2017
Isabella Piassi Godói, Vânia Eloisa de Araújo, Brian B Godman   +2 more
exaly  

Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine

Journal of Infectious Diseases, 2016
Annelies Wilder-Smith, Terry M Nolan
exaly  

Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years

Human Vaccines and Immunotherapeutics, 2012
Annelies Wilder-Smith, Sophia Archuleta
exaly  

Replication and Excretion of the Live Attenuated Tetravalent Dengue Vaccine CYD-TDV in a Flavivirus-Naive Adult Population: Assessment of Vaccine Viremia and Virus Shedding

Journal of Infectious Diseases, 2017
Joseph Torresi
exaly  

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

Lancet, The, 2012
Chukiat Sirivichayakul, Kriengsak Limkittikul, Simonetta Viviani   +2 more
exaly  

Dengue vaccine: hypotheses to understand CYD-TDV-induced protection

Nature Reviews Microbiology, 2015
exaly  

Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis

BMJ Open, 2019
Bruno Rodrigues Rosa
exaly  

Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations

Frontiers in Pharmacology, 2017
Juliana Alvares, Brian B Godman
exaly